News
Stéphanie Moy
+33 (0)6 32 55 85 48
s.moy@quantumsurgical.com
Webinar on Robotic- Assisted Ablation for Abdominal Tumors: Expert Perspectives and Case Reviews
Join Quantum Surgical and leading experts from Miami Cardiac and Vascular Institute, Miami Cancer Institute, a part of Baptist Health South Florida for a webinar on robotic-assisted ablation for abdominal tumors. Learn how cutting-edge robotic technology is transforming minimally invasive treatments and building a pioneering interventional oncology program in the U.S.
The guest speakers include Govindarajan Narayanan, MD, Chief of Interventional Oncology, Constantino Santiago Peña, MD; Ripal Gandhi, MD; Gina Landinez, MD; and Daniela Garcia, MD, Fellow.
Interventional oncology continues to play a pivotal role in addressing the increasing demands of the growing oncology market. With more patients being diagnosed earlier, the need for safe, efficient, and minimally invasive treatment options has never been greater. As hospitals seek cost-effective solutions, the demand for innovative cancer treatments rises steadily. Robotic-assisted technologies like Epione® are standardizing care delivery, offering enhanced precision, efficiency, and patient outcomes in treating abdominal tumors through percutaneous ablation.
Click here to register for our webinar featuring the first hospital in the US to adopt robotic-assisted technology and hear how it’s changed their approach in interventional cancer care.
Quantum Surgical receives the 2024 Award from the French National Institute of Industrial Property in the Start-up category
Montpellier, December 2, 2024 - Launched in 1991, the Awards of the French National Institute of Industrial Property annually honor innovative and promising companies that place industrial property at the core of their development strategy. Quantum Surgical has been awarded the prize in the Start-up category.
Specializing in medical robotics and artificial intelligence, Quantum Surgical develops solutions to treat cancer in a more targeted and less invasive way.
Its flagship innovation, the Epione® robotic platform, has been on the market since 2021. It assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.
To date, more than 700 patients worldwide have been treated with Epione. Quantum Surgical aims to become a global leader in its field. Since its inception, the company has focused all its efforts on innovation: half of its team is dedicated to research and development, and its technologies are protected through patent filings.
Quantum Surgical pursues its operations expansion in Europe and the United States. Its Epione platform is CE-marked in Europe for abdominal and lung tumors and FDA-approved in the United States for abdominal tumors.
"Our industrial property strategy takes into account the international dimension of our innovations. Indeed, we are continuing our development in Europe and the United States, and at the same time, we are striving to offer our treatment to as many patients as possible. The Epione solution is currently available in about ten hospitals worldwide. We are proud to have brought together teams to create innovative and unique robots that assist both physicians and patients," explains Bertin Nahum, CEO of Quantum Surgical.
About Quantum Surgical
Quantum Surgical was founded in 2017 by CEO and co-founder Bertin Nahum and a team of pioneering innovators specializing in developing and commercializing advanced medical robotics. Headquartered in Montpellier, France, and Miami, Florida, Quantum Surgical has a growing team of over 120 dedicated professionals.
The Epione platform is designed to revolutionize cancer care by enabling earlier and more precise treatments. Epione is FDA-cleared for CT-guided percutaneous ablation procedures in the abdomen and is compatible with most FDA-approved ablation devices.
More information: www.quantumsurgical.com
Press Contact QuantumSurgical
Stéphanie Moy
Tel.: +33 (0)6 32 55 85 48
‘I Literally Didn’t Have Any Organs Left to Take Out’: How Epione®, a Minimally Invasive Robotic-Assisted Ablation Technology Transformed a Cancer Patient’s Life
A groundbreaking achievement: Miami Cardiac and Vascular Institute and Miami Cancer Institute, part of Baptist Health South Florida, led the nation as the first to offer Epione, a cutting-edge robotic-assisted technology for minimally invasive ablation procedures. This technology has successfully transformed care for countless cancer patients.
For patients like Jose, the battle against renal cell carcinoma is a marathon, not a sprint. Diagnosed in 2006, Jose underwent a complete nephrectomy, removing his entire left kidney. Last year, his journey took another challenging turn when he developed metastatic lesions in the lower lobe of his right lung and pancreas, requiring additional surgeries. But when a lesion appeared in his remaining kidney, surgery was no longer an option.
Facing this new hurdle, Jose’s team at Miami Cancer Institute turned to innovation. They recommended a minimally invasive procedure using Epione, a robotic-assisted technology for percutaneous ablation. Given the tumor type and its location, the team decided that cryoablation would provide Jose with the best possible outcome.
Dr. Ripal Gandhi, a vascular and interventional radiologist with over 15 years of experience, led Jose’s procedure. A global thought leader in minimally invasive therapies, Dr. Gandhi specializes in cutting-edge treatments for cancer, peripheral vascular disease, and more. His expertise and Epione’s advanced technology offered Jose a new path forward in his ongoing fight against cancer.
“The benefits of the Epione robotic system is it allows us to treat patients more precisely, we are able to access lesions which sometimes would take us hours or sometimes we could not treat at all,” shared Dr. Gandhi. “It allows us to treat patients who may have a lot of issues, who might have a lot of comorbidities, who might not be safely placed under anesthesia for a long period of time, where you can treat the patient much faster and do it safely.”
For Dr. Gandhi and his colleagues at Miami Cancer Institute, Epione has been a ‘game-changing technology’.
“When we are doing procedures robotically versus freehand, these procedures are done much faster. It’s really beneficial for everybody; it’s beneficial for the patient as they are under anesthesia for a shorter period of time, and we are able to do more procedures in the room. Patients can have a faster recovery,” adds Dr. Gandhi.
Thanks to this minimally invasive, cutting-edge procedure, Jose has been given a renewed sense of hope and a cancer-free future. He and his family are deeply grateful to Dr. Gandhi and the team at Miami Cancer Institute for their exceptional care. At his most recent follow-up appointment, Jose was thrilled to share that he remains cancer-free, a testament to the power of innovation and expertise in modern medicine.
Quantum Surgical obtains ISO 27001:2023 certification
Montpellier and Miami, December 11th 2024 – A specialist in the minimally invasive treatment of cancerous tumors, Quantum Surgical has just obtained ISO 27001:2023 certification, which attests to the security and rigor of its data management system.
The ISO/IEC 27001:2023certification demonstrates that Quantum Surgical has implemented a robust and effective system to manage risks related to the security of its data or the data it processes. This system complies with the best practices and principles outlined in this international standard. Quantum Surgical's clients can therefore be assured of the security of their data.
"Information and data security has always been a cornerstone of Quantum Surgical's development. Our Epione solution is available in about ten hospitals worldwide; and obtaining the international ISO 27001:2023 certification reflects our commitment to our clients and users," explains Bertin Nahum, CEO and co-founder of Quantum Surgical.
Quantum Surgical develops the Epione® robotic platform, which has been on the market since 2021.It assists practitioners in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.
Epione is now used in about ten centers worldwide, with over 700 patients already treated.
About Quantum Surgical
Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 110 employees, the company is headquartered inMontpellier, France, and has offices in Miami, Florida.
Its Epione® platformis dedicated to the curative and early treatment of cancers. Quantum Surgicalthus offers a new approach to cancer treatment by standardizing access to care.More patients can benefit from innovative, better targeted and less invasivetreatments. Hundreds of patients have already been treated worldwide.
Quantum Surgical wasawarded the prestigious Prix Galien USA in 2022, the equivalent of the NobelPrize for biopharmaceutical research, and joined in 2023 the governmentalFrench Tech 2030 program in 2023 that supports top emerging actors indisruptive innovation.
More information: www.quantumsurgical.com
Press contact Quantum Surgical
Stéphanie Moy
s.moy@quantumsurgical.com
Tel. : +33(0)6 32 55 85 48
The Paoli-Calmettes Institute adopts Epione®, Quantum Surgical’s minimally invasive surgical robot that destroys cancerous tumors
Marseille, March 14th,2024 – The Paoli-Calmettes Institute (IPC) acquired Epione®, Quantum Surgical’s robotic platform which enables curative and early treatment of tumors. The first patient was treated yesterday in Marseille. The IPC is the 4th center in the world to offer its patients this minimally invasive treatment in which one or several needles are inserted through the skin into the tumor to destroy it.
Epione® is a technology that enables interventional radiologists toperform safe and effective percutaneous tumor ablations, a minimally invasive treatment where one or more needles are inserted through the skin to destroy the tumor. This platform is designed to plan, target, execute, and confirm the ablation of abdominal and pulmonary tumors, with other locations currently under study.
After Baptist Health Hospital in Miami, Gustave Roussy Institute in Villejuif, and Hospices Civils de Lyon, the Paoli-Calmettes Institute is the fourth center in the world to acquire the Epione® robot.
For over 10 years, at IPC, patients have been benefiting from these percutaneous ablation techniques to treat small tumors, either using heat (radiofrequency, microwave) or cold (cryotherapy). These treatments are performed within a dedicated unit consisting of three operating rooms with two interventional scanners and an angiography table. The advent of robotics in interventional radiology will further enhance the safety and precision of these procedures.
Professor Norbert Vey, General Director of IPC, explains: "IPC is a cancer center dedicated to offering increasingly effective treatments to its patients. IPC's strategy now includes developing minimally invasive interventions to enhance patients' quality of life and reduce after-effects. By offering minimally invasive tumor ablations, IPC will be able to treat more patients and improve their comfort."
Quantum Surgical and the Paoli-Calmettes Institute have signed a scientific and clinical partnership agreement focusing on clinical studies, with Quantum Surgical acting as the promoter, as well as pioneering topics in robotics.
"Epione® is a unique robotic solution that enables the treatment of tumors in hard-to-reach areas, where only a few experts can intervene. With the robot, these minimally invasive treatments will be standardized, allowing us to provide this curative treatment to a larger number of patients," adds Dr. Gilles Piana, Head of the Medical Imaging Department at IPC.
"This new acquisition by the Paoli-Calmettes Institute in Marseille marks a significant milestone for Quantum Surgical and is a recognition of the benefits of Epione®. We are delighted that an increasing number of patients can benefit from our minimally invasive technology, which destroys tumors while improving their comfort," states Bertin Nahum, President and Co-founder of Quantum Surgical.
Cancer: Quantum Surgical organizes its first European symposium at ECIO 2024 conference
Montpellier, April 22nd, 2024 – Quantum Surgical will attend the European Conference on Interventional Oncology (ECIO) held in Mallorca from April 28th to May 1st, dedicated to top interventional oncology KOLs. Quantum Surgical will present itsEpione® robotic ablation platform and organize its first European symposium, during which three key users will share their robotic experience: Pr. Thierry de Baere (Gustave Roussy, France), Pr. Laurent Milot (Hospices Civils de Lyon, France) and Dr. Gilles Piana (Institut Paoli-Calmettes, France).
French medical robotics company Quantum Surgical will take part in the ECIO, which brings together top interventional oncology KOLs and experts on minimally invasive cancer care for knowledge exchange in the field.
Quantum Surgical will thus present its Epione® robotic platform dedicated to the early and curative treatment of tumors during the event held in Mallorca April 28 – May 1st and will host its first European symposium on “Epione®: How Robotics is Creating the Next Generation of IO Programs”.
During the symposium, users of Epione®, Pr. Thierry de Baere (Gustave Roussy, France), Pr. Laurent Milot (Hospices Civils de Lyon, France) and Dr. Gilles Piana (Institut Paoli-Calmettes, France) will share how robotics hasc hanged their way to perform and to teach percutaneous ablation procedures, as well as how they have been able to implement a robotics program in their institutions.
The symposium will be organized on Sunday, April 28, 18:30 – 18:55,Auditorium 2.
Epione® is a robot-assisted technology that allows physicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment in which one or several needles are inserted through the skin to the tumor todestroy it.
Epione® is CE marked in Europe for abdomen and lung tumors, and FDA cleared for abdominal tumors. Hundreds of patients have already been treated worldwide.
Cancer: 400 patients have already been treated with Epione®, Quantum Surgical’s robot designed to treat tumors
Montpellier, February 26th 2024 - Since it was launched in 2021, 400 patients have already been treated with Epione®, Quantum Surgical's platform, worldwide.
Epione® is a technology that allows physicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment in which one or several needles are inserted through the skin to the tumor to destroy it.
400 patients have already benefited from this curative treatment worldwide, including in the United States where Quantum Surgical sold its first robot in December 2023.
"Our mission is to enable as many patients as possible to benefit from effective and high-value-added treatment, and the entire Quantum Surgical team is delighted that 400 of them have already been able to benefit from Epione® technology to treat their tumors and lesions. This exponential growth demonstrates the utility of our robot,both in the United States and in France," says Bertin Nahum, President andCo-founder of Quantum Surgical.
Epione® is CE marked in Europe for abdomen and lung tumors, and FDA cleared for abdominal tumors. Epione® is also available at the Gustave Roussy Cancer Center in Villejuif, as well as at the Hospices Civils de Lyon and in Miami.
About Quantum Surgical
Quantum Surgical is a French medical robotics company founded in Montpellier. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.
Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, th eequivalent of the Nobel Prize for biopharmaceutical research and joined the governmental French Tech 2030 program that supports top emergingactors in disruptive innovation.
More information: www.quantumsurgical.com
.png)
100th Patient Milestone with Epione® Achieved at US Hospital
MIAMI,FL– May 8, 2024 – This week, Epione will celebrate another milestone at a leading cancer institute where the 100th patient will be treated using the technology. Epione, a robotic-assisted platform used in interventionaloncology, is designed to support physicians during minimally invasive, percutaneous ablations of abdominal tumors.
“Manypatients cannot undergo extensive surgery, or their tumors are considered inoperable for various reasons, and image-guided ablation is a minimally invasive treatment option for them,” shared Dr. Govindarajan Narayanan, Chief of Interventional Oncology with Miami Cancer Institute and Miami Cardiac & Vascular Institute, part of Baptist Health South Florida. “Robotic-assisted ablations allow physicians to plan and place the ablation probe with precision and obtain post-procedure confirmation of ablation success while reducing the radiation exposure to the patient and the physician.”
A minimally invasive procedure, Epione uses CT-guided navigation for the percutaneous ablation of tumors in the abdomen. A robotic arm guides physicians to the best entry point, allowing them to precisely insert a needle while avoiding critical structures. Because physicians can quickly perform these procedures, patients may be able to go home the same day.
"Our mission has been to develop state-of-the-art technology that has the potential to help physicians improve the lives of patients diagnosed with cancer," said Bertin Nahum, CEO and co-founder of Quantum Surgical. "With yet another significant milestone, Epione has proved its relevance for interventional oncology. We aim to expand the availability of less invasive treatments for a greater number of patients."
Quantum Surgical receives €30 million loan from the European Investment Bank, with the support of InvestEU
· The Montpellier (France)-based medical robotics company Quantum Surgical, has secured a financing of €30 million from the European Investment Bank (EIB).
· This funding will support the global commercial development of Epione®, Quantum Surgical's platform dedicated to the curative and early treatment of inoperable tumors in the abdomen and lungs.
· This investment benefits from the guarantee of the Invest EU program established by the European Commission.
This operation aims to accelerate the commercialization of the medicalrobot Epione, designed for minimally invasive treatment of abdominal and lung cancer.
After selling its first robot in the United States in December 2023 and the acquisition of Epione® by the Paoli-Calmettes Institute in Marseille in March 2024, the financing will accelerate the commercial development of the company. This is the second loan granted by the EIB to Quantum Surgical, following an initial financing in 2021 for the commercial launch of Epione®.
Epione® is a technology that enables interventional radiologists to perform safe and effective percutaneous tumorablations, a minimally invasive treatment where one or more needles are inserted through the skin to destroy the tumor.
Epione® is CE marked in Europe for abdomen and lung tumors, and FDA cleared for abdominal tumors. Epione® is available in France, at the Gustave Roussy Cancer Center in Villejuif, at the Hospices Civils de Lyon as well as at the Paoli-Calmettes Institute in Marseille, and in Miami, United States.
More than 4 million new cases of abdominal and lung cancers are diagnosed each year worldwide. Several hundred patients have already been treated worldwide using Quantum Surgical's medical platform.
"At Quantum Surgical, our goal is to provide patients with innovative and effective treatment on a global scale. We are delighted to receive support once again from the EIB. This demonstrates that our technology is destined for global adoption to revolutionize cancer treatment," says Bertin Nahum, CEO and co-founder of Quantum Surgical.
"Already a partner of Quantum Surgical, the EIB is pleased to once again support the development of a surgical robot that has proven its worth in the medical field. This €30 million financing demonstrates Europe's commitment to supporting innovation and promising technologies in the healthcare sector, essential for improving the lives and well-being of patients on a much larger scale," stated Ambroise Fayolle, Vice President of the European Investment Bank.
Pr. Laurent Milot (Lyon) and Dr. Govindarajan Naranayan (Miami) to join Quantum Surgical Scientific Advisory Board
Montpellier, January 18th 2024 – French medical robotics company Quantum Surgical expands its Scientifc Advisory Board (SAB) with the appointments of Pr. Laurent Milot (Hospices Civils de Lyon) and Dr. Govindarajan Narayanan (Miami). The physicians will bring their expertise to develop the adoption of Epione®, Quantum Surgical’s tumor-treating robotic platform, and provide guidance for and participate to the dissemination of clinical outcomes.
French medical robotics Quantum Surgical announced today the expansion of its Scientific Advisory Board (SAB) with the appointment of Pr. Laurent Milot, Deputy Chief Vascular & Interventional Radiology at the Hospices Civils de Lyon and Dr. Govindarajan Narayanan, Chief of interventional oncology in Miami.
“We are honored and delighted to expand our SAB with the appointment of Pr. Laurent Milot and Dr. Govindarajan Narayanan, seasoned users of Epione®. Their experience and advice, combined with those of the other SAB members’, will help and support the adoption of Quantum Surgical’s tumor-treating robot in the European and American markets” says Bertin Nahum, CEO and co-founder of Quantum Surgical.
“We are thrilled to have Pr. Milot and Dr. Narayanan, two of our top users, joining the SAB. Their experience with Epione® will be extremely valuable to advise on Quantum Surgical's clinical strategy and help develop its adoption” says Laetitia Messner, Chief Clinical Officer at Quantum Surgical.
The Quantum SurgicalSAB is a multi-disciplinary board composed of international experts in thefield of image-guided interventional oncology:
- Professor Steven D. Colquhoun (US), Professor of Surgical Oncology, Medical College of Georgia (GA).
- Professor Thierry De Baere (FR), Interventional radiologist at Gustave Roussy Cancer Center (Villejuif).
- Professor Nishita Kothary (US), Interventional Radiologist at Stanford University Medical Center (Stanford, CA).
- Professor David C. Madoff (US), Interventional Radiologist at Yale New Haven Hospital (New Haven, CT).
- Professor Laurent Milot (FR), Deputy Chief Vascular & Interventional Radiology at the Hospices Civils de Lyon.
- Dr. Govindarajan Naranayan (USA), Chief of interventional oncology in Miami.
Professor Luigi Solbiati (IT), InterventionalRadiologist, pioneer of percutaneous liver ablation techniques, Professor ofRadiology at Humanitas University (Rozzano – Milan), is honorary member of thisScientific Advisory Board.
Epione® is a robot-assisted technology that allows physicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment in which one or several needles are inserted through the skin to the tumor to destroy it.
Epione® is CE marked in Europe for abdomen and lung tumors, and FDA cleared for abdominal tumors. Epione® is available at the Gustave Roussy Cancer Center in Villejuif, as well as at the Hospices Civils de Lyon and in Miami. Hundreds of patients have already been treated worldwide.
%20(1)-min.png)
An exciting and busy year 2024 at Quantum Surgical
It’s been a busy and exciting year at Quantum Surgical. Here are some of our highlights:
- The Paoli-Calmettes Institute in Marseille, France, acquired Epione. About 30 patients have since been treated by Dr Piana and his team.
- Quantum Surgical received €30 million financing from the European Investment Bank.
- Quantum Surgical launched the Epibone clinical study to assess Epione®’s performance to treat bone tumors.
- Rush University System for Health in Chicago (IL) acquired Epione®.
- Dr. Naranayan and his team celebrated the 150th patient treated at Baptist Health, Miami (FL).
- Quantum Surgical received the French National Institute of Industrial Property Award in the Start-up category.
- Quantum Surgical organized a webinar with the Baptist Health IO team.
- Quantum Surgical’s first symposiums took place in USA at Spectrum in Miami and in Europe at ECIO in Mallorca, Spain.
- Quantum Surgical obtained ISO 27001:2023 certification which attests to the security and rigor of its data management system.
- Bertin Nahum, CEO and co-founder, spoke at CES in Las Vegas, the biggest tech event in the world.
- Lucien Blondel, our CTO and co-founder, received the Surgical Robotics Industry Award of Industry Leadership.
- LSI Europe invited Quantum Surgical to present the Epione® solution in Lisbon, Portugal.
- Quantum Surgical and Epione® attended various events worldwide: Spectrum in Miami, FL; ECIO in Mallorca, Spain; CIRSE in Lisbon, Portugal; Medpeers in Amsterdam, The Netherlands…
- And 720+ patients have been treated overall!
We are really happy with everything we have achieved together as a team and with our partners, we look forward to 2025!
‘I Literally Didn’t Have Any Organs Left to Take Out’: How Epione®, a Minimally Invasive Robotic-Assisted Ablation Technology Transformed a Cancer Patient’s Life
A groundbreaking achievement: Miami Cardiac and Vascular Institute and Miami Cancer Institute, part of Baptist Health South Florida, led the nation as the first to offer Epione, a cutting-edge robotic-assisted technology for minimally invasive ablation procedures. This technology has successfully transformed care for countless cancer patients.
For patients like Jose, the battle against renal cell carcinoma is a marathon, not a sprint. Diagnosed in 2006, Jose underwent a complete nephrectomy, removing his entire left kidney. Last year, his journey took another challenging turn when he developed metastatic lesions in the lower lobe of his right lung and pancreas, requiring additional surgeries. But when a lesion appeared in his remaining kidney, surgery was no longer an option.
Facing this new hurdle, Jose’s team at Miami Cancer Institute turned to innovation. They recommended a minimally invasive procedure using Epione, a robotic-assisted technology for percutaneous ablation. Given the tumor type and its location, the team decided that cryoablation would provide Jose with the best possible outcome.
Dr. Ripal Gandhi, a vascular and interventional radiologist with over 15 years of experience, led Jose’s procedure. A global thought leader in minimally invasive therapies, Dr. Gandhi specializes in cutting-edge treatments for cancer, peripheral vascular disease, and more. His expertise and Epione’s advanced technology offered Jose a new path forward in his ongoing fight against cancer.
“The benefits of the Epione robotic system is it allows us to treat patients more precisely, we are able to access lesions which sometimes would take us hours or sometimes we could not treat at all,” shared Dr. Gandhi. “It allows us to treat patients who may have a lot of issues, who might have a lot of comorbidities, who might not be safely placed under anesthesia for a long period of time, where you can treat the patient much faster and do it safely.”
For Dr. Gandhi and his colleagues at Miami Cancer Institute, Epione has been a ‘game-changing technology’.
“When we are doing procedures robotically versus freehand, these procedures are done much faster. It’s really beneficial for everybody; it’s beneficial for the patient as they are under anesthesia for a shorter period of time, and we are able to do more procedures in the room. Patients can have a faster recovery,” adds Dr. Gandhi.
Thanks to this minimally invasive, cutting-edge procedure, Jose has been given a renewed sense of hope and a cancer-free future. He and his family are deeply grateful to Dr. Gandhi and the team at Miami Cancer Institute for their exceptional care. At his most recent follow-up appointment, Jose was thrilled to share that he remains cancer-free, a testament to the power of innovation and expertise in modern medicine.
Stäubli Robotics and Quantum Surgical enter into a strategic partnership
Montpellier, France, June 23, 2020 - Stäubli Robotics and Quantum Surgical, both European leaders in their respective fields, are joining forces to create a Centre of excellence in oncology robotics.
Family-owned Stäubli Robotics, a division of the Stäubli Group, is a leading international player in industrial automation. Staubli Robotics designs, manufactures, and markets a complete range of robots adapted to all needs, even the most specific, such as in the field of medicine.
Quantum Surgical, an innovative surgical robotic company, is developing an innovative solution, a combination of powerful software and robotic platform for minimally invasive therapies in liver cancer.
This strategic partnership aims to combine this savoir-faire to strengthen the role of robotics in minimally invasive cancer treatments and to build a world leader.
A memorandum of understanding has been signed by the two parties.
"We are extremely grateful and proud that Quantum Surgical confirms their trust in Stäubli as a partner of choice for this new patient care application, at the service of human well-being. We are excited to contributing to Quantum's vision together, with a long-term partner that stimulates us on a daily basis and makes us better." announces Gerald Vogt, General Manager Stäubli Robotics.
"We are honored to work with Stäubli, a company recognized for its technological excellence and savoir-faire, in order to share a vision of robotics and automation in healthcare," explains Bertin Nahum, President, and Founder of Quantum Surgical.
World Premiere for Quantum Surgical's Medical Robot at Montpellier University Hospital
Montpellier, France, June 8, 2020 - On June 4, 2020, Professor Boris GUIU and his team at Montpellier University Hospital (France) successfully treated a 56-year-old patient with liver tumor using Quantum Surgical's medical robot.
Quantum Surgical, an innovative surgical robotic company founded in 2017, developed its robot in record time thanks to a highly talented and experienced multidisciplinary team.
This device, a combination of powerful software and robotic platform, assists the physician in performing safer, more efficient and less invasive oncology treatments.
Through Quantum Surgical’s device, Professor GUIU was able to plan the procedure on the patient's 3D images and then perform the intervention with high precision, guided by the robot.
This world premiere was accomplished as part of a clinical trial that is being carried out in three University Hospitals in France.
"This first thermoablation with robotic assistance completely treated the tumor with an excellent margin. We couldn't have done better. The patient is doing very well. He went home the very next day, ready to return to normal life," explains Professor Boris GUIU, Interventional Radiologist, Head of the Department of Diagnostic and Interventional Radiology of Saint Eloi (Montpellier University Hospital)
"With this world premiere, Quantum Surgical is making a striking mark in the medical robotics industry and strengthening its ambition," announces Bertin NAHUM, President and Founder of Quantum Surgical.
Quantum Surgical expands its Scientific Advisory Board with Professor Kothary and Professor Colquhoun
Montpellier, France, June 2, 2020 - Quantum Surgical, an innovative surgical robotics company expands its Scientific Advisory Board (SAB) with the appointment of two leading North American physicians.
The Quantum Surgical Scientific Advisory Board (SAB) is a multi-disciplinary board composed of international experts in the field of image-guided interventional oncology:
• Professor Luigi Solbiati (IT), Interventional Radiologist, pioneer of percutaneous liver ab-lation techniques, Professor of Radiology at Humanitas University (Rozzano - Milan),
• Professor Boris Guiu (FR), Interventional Radiologist, Head of the Department of Diag-nostic and Interventional Radiology of Saint Eloi (Montpellier University Hospital),
• Professor David C. Madoff (US), Interventional Radiologist at Yale New Haven Hospital (Yale University)
• Professor Nishita Kothary (US), Interventional Radiologist at Stanford University Medical Center (Stanford)
• Professor Steven D. Colquhoun (US), Liver surgeon, specialized in robotic surgery at UC Davis Comprehensive Cancer Center (Sacramento),
Professor Guy Vallancien (FR), urology surgeon, and pioneer of laparoscopic and robotic sur-gery, is an honorary member of this scientific advisory board.
Quantum Surgical is therefore reinforcing its collaboration with clinical experts as part of its devel-opment projects to strengthen its strategy with regard to the European and American markets.
"We are highly honored and delighted to be able to put to good use all the precious advice pro-vided by these internationally renowned physicians and be accompanied during the clinical development of our solution," explains Bertin Nahum, CEO, and co-founder of Quantum Surgical.
Quantum Surgical forms collaboration with PA-HP for AI Research in Ear-ly Cancer Treatment
Montpellier, France, February 11, 2020 – Quantum Surgical, an innovative company specializing in medical robotics, and AP-HP (Assistance Publique – Hôpitaux de Paris) have announced their collaboration on a future robotic solution.
This collaboration is part of a research project led by Professor Valérie Vilgrain, Head of the Radiology Department at Beaujon Hospital, AP-HP. The study is based on health data from patients admitted to AP-HP for liver tumor ablation, collected within the AP-HP’s Health Data Warehouse (EDS).
This partnership enables Quantum Surgical to access these data in order to develop and evaluate, together with radiologists, artificial intelligence algorithms aimed at facilitating minimally invasive treatments for liver cancer.
The project has received approval from the AP-HP EDS Scientific and Ethics Committee.
“We are honored and delighted by this collaboration. These data will allow us to expand use cases and advance medical image analysis as part of our artificial intelligence project,” said Bertin Nahum, President and Founder of Quantum Surgical.
“AI research is an excellent opportunity to foster academic–industry collaborations,” said Professor Valérie Vilgrain, Head of the Radiology Department at Beaujon Hospital, AP-HP.
Quantum Surgical receives €2 million from BpiFrance for the development of its next-gen robotized platform
Montpellier, France, Tuesday, January 21, 2020 – Quantum Surgical, an innovative company specializing in medical robotics, announces it has secured “Deeptech” development funding from Bpifrance for the development of its robotic platform designed to assist with minimally invasive surgical treatments in oncology.
This funding comes from Bpifrance’s “Deeptech” fund, which includes grants and repayable advances. Its objective is to support companies engaged in “Deeptech”-certified technological innovation projects involving industrial research and/or experimental development, with the aim of developing innovative products, processes, or services that offer tangible prospects for industrialization and commercialization.
“We are very pleased to receive this new support from Bpifrance, which is backing us in this exciting venture. This funding will allow us to accelerate the development of our innovative platform to benefit both patients and practitioners,” said Bertin Nahum, President and Founder of Quantum Surgical.
Quantum Surgical obtains ISO 13485: 2016 certification
Montpellier,November 28, 2019 - Quantum Surgical, an innovative surgical robotics company,today announced that it has obtained ISO 13485: 2016 certification for the"Design & development of computer assisted surgical systems" by TheCertification Body of TUV Rheinland.
This internationallyrecognized certification confirms that the quality management system meets thespecific standards required for the design and development of Quantum'stechnology.
"ObtainingISO 13485: 2016 certification is an important step for Quantum Surgical. It isan essential instrument to meet regulatory requirements and shows the company’sdetermination to be part of an industrial approach that meets the higheststandards of safety, performance and reliability” explains Bertin Nahum, CEOand co-founder of Quantum Surgical.
What isthe ISO 13485: 2016 standard?
The ISO13485: 2016 standard, recognized worldwide, specifies requirements for aquality management system where an organization needs to demonstrate itsability to provide medical devices and related services that consistently meetcustomer and applicable regulatory requirements. Such organizations can beinvolved in one or more stages of the life cycle, including design anddevelopment, production, storage and distribution, installation, or servicingof a medical device and design and development or provision of associatedactivities (e.g. technical support). ISO 13485:2016 can also be used bysuppliers or external parties that provide product, including qualitymanagement system-related services to such organizations.
Quantum Surgical and Montpellier-Nîmes Faculty of Medicine are co-developing a new training course
Montpellier, November 18, 2019 – For several months now, Quantum Surgical and the Faculty of Medicine Montpellier-Nîmes have been co-developing an unprecedented training program for companies, aimed at giving their employees a better understanding of the medical field. This hospital-university training program for companies will be led by professors, physicians, and healthcare professionals. Professor Michel Mondain, Dean of the Faculty of Medicine Montpellier-Nîmes, and Professor Boris Guiu, University Professor and Hospital Practitioner at Montpellier University Hospital and Head of Diagnostic and Interventional Radiology at Saint-Eloi Hospital, are working together to mobilize academic resources for the first session, scheduled for November 22.
This unique training program will initially offer two modules designed to strengthen employees' knowledge in the healthcare field. The first module will focus on foundational topics in surgery, anesthesia, and interventional radiology, leading into a more specialized section on liver cancer and percutaneous ablation.
This initiative reflects a strong commitment to fostering greater collaboration between healthcare professionals and those working on the technical side to build the medicine of tomorrow.
Founded in 2017 in Montpellier, Quantum Surgical is a French startup that puts innovation at the service of healthcare. With cutting-edge expertise and a team of sixty employees, the company is developing a unique solution dedicated to the minimally invasive treatment of liver cancer.
Quantum Surgical is committed to nurturing versatility and the sharing of expertise and experience within its teams. Through this initiative, the company aims to take its support for employees to the next level.
Aware of the major changes transforming the healthcare sector and the growing need for training among technical professionals, the Faculty of Medicine Montpellier-Nîmes is mobilizing its academic resources to meet the economic needs of industry. The Faculty has worked closely with Quantum Surgical to design a tailor-made training program aligned with the company’s specific needs.
Quantum Surgical establishes its Scientific Advisory Board (SAB) around international oncology experts
Montpellier, France, May 6, 2019 – Quantum Surgical, an innovative company specializing in medical robotics, announces the creation of its Scientific Advisory Board, which held its first meeting on April 8 in Amsterdam.
This Scientific Advisory Board is composed of leading multidisciplinary experts who are internationally recognized in the field of image-guided interventional oncology:
- Prof. Guy Vallancien (France) – Urological surgeon, pioneer in laparoscopic and robotic surgery, member of the French National Academy of Medicine, the Parliamentary Office for the Evaluation of Scientific and Technological Choices, and founder of the European School of Surgery;
- Prof. Luigi Solbiati (Italy) – Interventional radiologist, pioneer of percutaneous liver ablation techniques, former Head of the Oncologic Interventional Radiology Department at Busto Arsizio Hospital (Varese, Lombardy);
- Prof. David C. Madoff (USA) – Interventional radiologist, Vice Chair for Academic Affairs at NewYork-Presbyterian/Weill Cornell Hospital, and former Head of Interventional Radiology;
- Prof. Boris Guiu (France) – Interventional radiologist, Head of the Diagnostic and Interventional Radiology Department at Saint-Eloi Hospital – University Hospital of Montpellier, and Professor at the Faculty of Medicine in Montpellier.
The Quantum Surgical team will rely on these experts and benefit from their invaluable advice for the development and clinical launch of its product.
“We are honored to count such top-tier experts on our Scientific Advisory Board and are especially excited and grateful to benefit from their insights and invaluable clinical experience. This Scientific Advisory Board is essential for the next steps in Quantum Surgical’s development strategy,” said Bertin Nahum, President and Founder of Quantum Surgical.
Quantum Surgical, Ally Bridge and LifeTech Scientific announce Three-Way China Joint Venture to develop innovative surgical robot for the treatment of liver cancer
HONG KONG, SHENZHEN, China, and Montpellier, France, April 4, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border life science investment group, announced today that it has entered into an agreement with LifeTech Scientific Corporation (SEHK: 1302) (“LifeTech”), a leading medical device company in China, and Quantum Surgical, an innovative surgical robotics company in France, to establish a three-way China joint venture (“JV”). The JV will focus on the R&D and commercialization of Quantum Surgical’s integrated surgical robot platform in China for interventional oncology with the first target indication being liver cancer. China represents more than 50% of the world’s incidence of liver cancer.
The formation of this JV follows ABG’s Series A investment in Quantum Surgical (May 2018), in which LifeTech also participated in the investment through its existing partnership with ABG. ABG initiated and led the design and formation of the JV, where LifeTech is the majority shareholder and responsible for the setup and operation of the China JV, including contributing market know-how to expedite product approval and commercialization in China.
“ABG is excited to form this new China JV with LifeTech and Quantum Surgical, both of which are our portfolio companies. This JV showcases a new model for Sino-foreign collaboration in medical technologies. The ABG team has been working closely with Quantum Surgical, led by Bertin Nahum, following our successful investment in — and exit from – its predecessor company Medtech SA. Quantum Surgical is a natural extension of the 2018 ABG-led US$300 million investment in GRAIL, a healthcare company whose mission is to detect cancer early, when it can be cured. Early cancer detection must be accompanied by more effective early treatment, which Quantum is developing,” said Frank Yu, ABG’s Founder, CEO and CIO. “LifeTech has been a very close partner since the ABG team invested in the company’s IPO in 2011. LifeTech has a proven track record in obtaining “green channel” fast-track approval and commercializing in China for some of the world’s most innovative medical technologies. This includes collaborations with global medtech companies in localizing best-in-class products,
as proven by its China partnership with Medtronic, a critical strategy for foreign technologies entering the China market. This JV highlights ABG’s unique strategic and operational value-add for our portfolio companies in China, the U.S. and Europe, and how we invest in and bring cutting-edge technologies to solve large, poorly met medical needs in China,” Frank Yu added.
“This is a win-win partnership, where LifeTech Scientific is introduced and advised by our strategic partner ABG to join forces with Quantum Surgical, a leading innovative surgical robot developer with a proven track record,” said Yue-Hui Xie, Chairman and CEO of LifeTech Scientific. “This marks another ground-breaking achievement for LifeTech, investing in and partnering with world-leading healthcare technology following our strategic cooperation with ABG, including our participation in the 2018 financing for GRAIL. Both investments underpin LifeTech’s new strategic focus in cancer prevention and treatment,” Yue-Hui Xie added, “Following our successful partnership with U.S.-based global medtech giant Medtronic, our China JV with Quantum Surgical of France represents a new milestone for strategic and operational partnership with European companies in China.”
“Quantum will set new standards for minimally invasive cancer treatment procedures with the first target indication being liver cancer. We believe that LifeTech’s regulatory expertise and established commercialization infrastructure in China, coupled with ABG’s truly global industry network and strong capital markets and deal-making capabilities, will enable Quantum Surgical to accelerate its market entry into China and benefit millions of cancer patients there,” said Bertin Nahum, Founder and CEO of Quantum Surgical.
Quantum Surgical, award-winner of the Occitanie Innovation call for projects under the Investing for the Future scheme for its artificial intelligence program
Montpellier, France, Monday, February 4, 2019 – Quantum Surgical, an innovative company specializing in medical robotics, has been selected as a winner of the call for projects launched by the French government and the Occitanie Region as part of the third phase of the Programme d’Investissements d’Avenir (Investments for the Future Program), operated by Bpifrance, for the development of its artificial intelligence project.
The call for projects, “Occitanie Innovation Projects,” aims to accelerate the emergence and growth of regional companies that are leaders in their field and have the potential for national reach.
Quantum Surgical is receiving €490,000 in funding, equally financed by the French government and the Occitanie Region in the form of a grant.
With this funding, Quantum Surgical has launched a research and innovation program focused on artificial intelligence technologies to support the practice of percutaneous ablation.
“We are grateful for this continued support from the French government, the Occitanie Region, and Bpifrance, who remain by our side on this new journey. This will enable us to accelerate the development of innovative tools to benefit both patients and healthcare practitioners,” said Bertin Nahum, President and Founder of Quantum Surgical.
Quantum Surgical completes first round of financing to accelerate the development of its robotic platform for minimally invasive therapies in liver cancer
Montpellier and Hong Kong, June 4, 2018 – Quantum Surgical SAS, a company specializing in the design of next-generation solutions for the minimally invasive treatment of cancer, announces the completion of its first capital raise with Ally Bridge Group (ABG), a global investment group focused on life sciences. This Series A funding is the first tranche of a total $50 million financing round led by Ally Bridge Group.
Quantum Surgical is developing a next-generation robotic platform dedicated to the minimally invasive treatment of liver cancer. As this disease is the second leading cause of cancer-related death and affects more than 800,000 new patients each year worldwide, Quantum Surgical aims to provide healthcare professionals with new tools to better serve patients by offering a genuine alternative to current treatments.
“Quantum Surgical’s ambition is to establish new standards in cancer treatment by enabling more patients to access innovative, targeted, and less invasive therapies. We are thrilled to be working once again with Ally Bridge Group after our successful collaboration in 2015–2016. This new partnership will allow Quantum Surgical to leverage the group’s strong industrial outlook, international network, and solid financial capacity, as well as its expertise in accessing major medical markets such as the United States, China, and Europe,” said Bertin Nahum, Founder and President of Quantum Surgical.
“ABG is excited to support the Quantum Surgical team led by Bertin Nahum once again in their entrepreneurial journey, following our successful investment in Medtech SA. The team is recognized and has a proven track record in the development and global commercialization of innovative surgical robots. ABG has worked closely with Quantum Surgical since its inception. Our partnership is now at the forefront of creating next-generation robotics to support interventional oncology treatments, particularly for patients with early-stage cancer,” said Frank Yu, Founder and CEO of Ally Bridge Group. “Quantum Surgical is a natural extension of ABG’s recent $300 million investment in GRAIL, an innovative U.S. company focused on the early detection of cancer. ABG has the expertise to forge strategic partnerships between emerging companies and industry leaders at a global level, especially across the U.S., China, and Europe.”
Webinar on Robotics in Image Guided Ablation
Discover the power of Robotics in Image Guided Ablation during our upcoming webinar, featuring a live Q&A. Get your questions answered by experts from around the world. Don't miss this insightful session brought to you by Spectrum Cancer and Quantum Surgical.
Topics include:
- Benefits and challenges of robotics during ablation procedures
- Learning curves
- How to approach administration about adopting robotics
- Case presentations
- And live Q&A
Join us for this virtual event with live Q&A.
Limited spots.
REGISTER NOW!
Webinar on Robotic- Assisted Ablation for Abdominal Tumors: Expert Perspectives and Case Reviews
Join Quantum Surgical and leading experts from Miami Cardiac and Vascular Institute, Miami Cancer Institute, a part of Baptist Health South Florida for a webinar on robotic-assisted ablation for abdominal tumors. Learn how cutting-edge robotic technology is transforming minimally invasive treatments and building a pioneering interventional oncology program in the U.S.
The guest speakers include Govindarajan Narayanan, MD, Chief of Interventional Oncology, Constantino Santiago Peña, MD; Ripal Gandhi, MD; Gina Landinez, MD; and Daniela Garcia, MD, Fellow.
Interventional oncology continues to play a pivotal role in addressing the increasing demands of the growing oncology market. With more patients being diagnosed earlier, the need for safe, efficient, and minimally invasive treatment options has never been greater. As hospitals seek cost-effective solutions, the demand for innovative cancer treatments rises steadily. Robotic-assisted technologies like Epione® are standardizing care delivery, offering enhanced precision, efficiency, and patient outcomes in treating abdominal tumors through percutaneous ablation.
Click here to register for our webinar featuring the first hospital in the US to adopt robotic-assisted technology and hear how it’s changed their approach in interventional cancer care.
